{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"description":"Participant response assessed after two cycles of therapy according to categories: 1) complete response, 2) partial response, 3) clinical improvement, 4) stable disease 5) progressive disease, 6) early death from malignant disease, 7) early death from toxicity, 8) early death because of other cause, or 9) unknown (not assessable, insufficient data).","groups":[{"description":"37.5 mg orally daily for 6-week cycle","id":"OG000","title":"Sunitinib"}],"paramType":"NUMBER","populationDescription":"All participants assessed for response.","reportingStatus":"POSTED","timeFrame":"After two 6-week treatment courses (12 weeks)","title":"Number of Participants With Objective Clinical Response to Sunitinib Therapy","type":"PRIMARY","unitOfMeasure":"participants"}